DOXYCYCLINE HYCLATE

Post-LOE

doxycycline hyclate

PharmaIN

ANDAORALTABLET

Approved

May 2005

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

DOXYCYCLINE HYCLATE (doxycycline hyclate) by PharmaIN is mechanism of action doxycycline has been shown to inhibit collagenase activity in vitro . Approved for pocket depth in patients with adult periodontitis. First approved in 2005.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of Action Doxycycline has been shown to inhibit collagenase activity in vitro . Additional studies have shown that doxycycline reduces the elevated collagenase activity in the gingival crevicular fluid of patients with adult periodontitis. The clinical significance of these findings is…

Indications (1)

pocket depth in patients with adult periodontitis

Clinical Trials (2)

NCT01087476Phase 2Unknown

Double-blind-randomized,Placebo Controlled Trial for Chemotherapy-associated Oral Mucositis Using Doxycycline Hyclate

Started May 2010

164 enrolled

Mucositis

NCT00688064Phase 3Completed

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

Started Aug 2008

459 enrolled

Severe Acne Vulgaris

Worked on DOXYCYCLINE HYCLATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.